Xilio Therapeutics, Inc.
XLODrugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
5wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How XLO's past catalysts played out
XTX202
Advanced Solid Tumor
vilastobart (XTX101)
Advanced Solid Tumor
XTX301
Advanced Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
XTX202 | Phase 2 | Advanced Solid Tumor | - | - |
vilastobart (XTX101) | Phase 2 | Advanced Solid Tumor | - | - |
XTX301 | Phase 2 | Advanced Solid Tumor | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Xilio Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Xilio Therapeutics, Inc.'s (XLO) pipeline across Phase 2. Its lead program is XTX202 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Xilio Therapeutics, Inc.'s next FDA catalyst?→
Xilio Therapeutics, Inc.'s (XLO) next tracked catalyst is a Earnings expected August 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track XLO biotech catalysts?→
Add XLO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Xilio Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.